Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial
Authors
Keywords
-
Journal
Canadian Journal of Anesthesia-Journal canadien d anesthesie
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-08
DOI
10.1007/s12630-020-01684-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
- (2020) Zunyou Wu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
- (2020) Dawei Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures
- (2020) Yixuan Wang et al. JOURNAL OF MEDICAL VIROLOGY
- Secondary attack rate and superspreading events for SARS-CoV-2
- (2020) Yang Liu et al. LANCET
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Clinical Characteristics of Coronavirus Disease 2019 in China
- (2020) Wei-jie Guan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia
- (2020) Qun Li et al. NEW ENGLAND JOURNAL OF MEDICINE
- Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 — United States, January–February 2020
- (2020) Rachel M. Burke et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
- (2020) Nature Microbiology
- Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data
- (2020) Natalie M. Linton et al. Journal of Clinical Medicine
- Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus-2
- (2020) Matthew P. Cheng et al. ANNALS OF INTERNAL MEDICINE
- Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic
- (2020) Matthew P. Cheng et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
- (2020) Adarsh Bhimraj et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- (2020) Xueting Yao et al. CLINICAL INFECTIOUS DISEASES
- Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)
- (2020) Waleed Alhazzani et al. CRITICAL CARE MEDICINE
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
- (2020) Philippe Gautret et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression
- (2020) Dan Zhou et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
- (2020) Jianjun Gao et al. BioScience Trends
- Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
- (2020) et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
- (2020) Katelyn A Pastick et al. Open Forum Infectious Diseases
- No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
- (2020) J.M. Molina et al. MEDECINE ET MALADIES INFECTIEUSES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now